


### COVID-19 IMPACT

This report has been affected by the COVID-19 pandemic. All forecasts and analysis have been revised to reflect the current view including the effect of the pandemic and associated recession.

# RESEARCH REPORT



# Immuno-Oncology Diagnostics

Market Forecasts for Immuno-Oncology Diagnostics  
**with COVID-19 Impact and Updates.**

Including Executive/Consultant Guides and Customized Forecasting/Analysis.  
2021 to 2025





Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

## Table of Contents

i. Market Guides.....	17
i. Situation Analysis & Impact of COVID-19 Pandemic .....	18
ii. Guide for Executives and Marketing Staff.....	21
iii. Guide for Investment Analysts and Management Consultants .....	22
1. Introduction and Market Definition .....	23
1.1 What are Immuno-Oncology Diagnostics? .....	24
1.2 Immuno-oncology – the looming cure .....	26
1.2.1 Immuno-oncology Diagnostics Takes a Leading Role.....	28
1.3 Market Definition .....	29
1.3.1 Market Size .....	29
1.3.2 Currency .....	29
1.3.3 Years .....	29
1.4 Methodology .....	30
1.4.1 Authors.....	30
1.4.2 Sources .....	30
1.5 U.S. Medical Market and laboratory Testing - Perspective .....	31
1.5.1 U.S. Medicare Expenditures for Laboratory Testing.....	32
2. Immunotherapy – Guide to Immune Technologies .....	34
2.0 The Immune System.....	35
2.0.1 Innate immune system .....	36
2.0.1.1 Surface barriers .....	37
2.0.1.2 Inflammation .....	38

2.0.1.3 Complement system .....	38
2.0.1.4 Cellular barriers.....	39
2.0.1.5 Natural killer cells.....	40
2.0.2 Adaptive immune system .....	41
2.0.2.1 Lymphocytes .....	41
2.0.2.2 Killer T cells .....	42
2.0.2.3 Helper T cells .....	44
2.0.2.4 Gamma delta T cells .....	45
2.0.2.5 B lymphocytes and antibodies.....	45
2.0.3 Tumor immunology – the immune surveillance system .....	47
2.1 Immuno Oncology Diagnostics.....	49
2.1.1 Checkpoint Assays .....	49
2.1.1.1 Outlook for Checkpoint Assays .....	54
2.1.2 Cytokine Assays .....	55
2.1.2.1 Outlook for Cytokine Assays .....	55
2.1.3 Genomic Germline .....	56
2.1.3.1 Outlook for Genomic Germline.....	57
2.1.4 Genomic Tumour .....	57
2.1.4.1 Outlook for Genomic Tumour .....	60
2.1.5 Tumor Microenvironment .....	61
2.1.5.1 Outlook for Tumor Micro Environment .....	62
2.1.6 Others.....	62
2.1.6.1 Outlook for Other Diagnostics .....	62
3. Industry Overview .....	63
3.1 Players in a Dynamic Market .....	64

3.1.1 Academic Research Lab.....	64
3.1.2 Diagnostic Test Developer.....	65
3.1.3 Genomic Instrumentation Supplier .....	65
3.1.3.1 Cell Separation and Viewing Instrumentation Supplier .....	66
3.1.4 Pharmaceutical/Reagent Supplier.....	66
3.1.5 Independent Testing Lab.....	66
3.1.6 Public National/regional lab .....	67
3.1.7 Hospital lab.....	67
3.1.8 Physician Lab .....	67
3.1.9 Audit Body .....	68
3.1.10 Certification Body.....	68
4. Market Trends.....	70
4.1 Factors Driving Growth.....	71
4.1.1 Outcome potential .....	71
4.1.2 Companion Diagnostics .....	72
4.1.3 Funding .....	72
4.1.4 Technology Environment .....	72
4.1.5 Target Solutions .....	73
4.2 Factors Limiting Growth .....	74
4.2.1 Complex Role of Diagnostics .....	74
4.2.2 Clinical Trials Role.....	75
4.2.3 Protocols .....	75
4.3 Diagnostic Technology Development .....	77
4.3.1 Combinations - Issues and Complexity .....	77
4.3.2 Shifting Role of Diagnostics.....	79

4.3.3 Multiplexing and Foundation One .....	80
4.3.4 The Disruption Dynamic .....	81
4.3.5 The Race for Biomarkers .....	81
4.3.6 The Next Five Years .....	82
5. Cancer Immuno-Oncology Diagnostics Recent Developments .....	83
5.1 Recent Developments – Importance and How to Use This Section .....	84
5.1.1 Importance of These Developments .....	84
5.1.2 How to Use This Section .....	84
Qiagen Expands Immuno-Oncology Portfolio .....	84
Immune Profiling System Redirected to Fight COVID-19 .....	85
IncellDx Awarded PD-L1 Detection Patent.....	88
FDA Approves CDx for Trastuzumab.....	88
Promega Nabs CE Mark for Microsatellite Instability IVD .....	89
ArcherDx partners with AstraZeneca for Immuno-Oncology .....	91
Germline Results Guides Precision Therapy .....	92
Agilent PD-L1 Assay Gets FDA Approval .....	96
Bayer, OrigiMed Form Companion Diagnostic Development Alliance .....	96
Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy .....	97
SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological Signatures .....	98
Biocare Medical Launches 7 Novel IVD Antibodies .....	99
Oncocyte to Acquire Insight Genetics for \$12M.....	100
Novigenix and BioLizard to develop NGS Based Diagnostic Algorithm .....	102
Biodesix and Immodulon Collaborate for Pancreatic Cancer Treatment .....	103
Generex to Merge with NuGenerex Immuno-Oncology .....	104

Cellgen Diagnostics and Genomic Testing Cooperative Partner to Develop Companion Diagnostics for Cancer Therapies .....	105
Hematogenix Launches FDA Approved Immuno-oncology Test for Triple-Negative Breast Cancer .....	106
Icon Acquires MolecularMD.....	107
Guardant Health to Develop Companion Diagnostic Tests for AstraZeneca .....	109
Tumor Mutational Burden as Predictor of Immunotherapy Success .....	110
6. Profiles of Key Immunotherapy Companies .....	114
10X Genomics.....	115
Abbott Laboratories .....	116
Abcam.....	118
Adaptive Biotechnologies .....	120
Aethlon Medical .....	121
Agena Bioscience .....	122
Angle plc .....	124
Apocell .....	125
ARUP Laboratories .....	126
Beckman Coulter.....	128
Becton Dickinson .....	129
Bioarray Genetics .....	131
BioCartis.....	132
Biocept .....	133
Biodesix Inc.....	135
BioFluidica .....	136
BioGenex.....	138
bioMérieux.....	140



Bio-Rad .....	141
Bio-Techne.....	142
Bristol-Myers Squibb .....	144
Cancer Genetics .....	146
Caris Molecular Diagnostics .....	148
CellMax Life .....	150
Charles River Laboratories .....	151
Chronix Biomedical .....	153
Circulogene .....	154
Clearbridge BioMedics .....	155
Clinical Genomics .....	157
Cynvenio .....	158
Cytolumina Technologies Corp. ....	159
CytoTrack .....	160
Dako (Agilent).....	161
Diagnologix LLC .....	163
Epic Sciences .....	164
Exosome Diagnostics.....	165
Fluidigm Corp.....	167
Fluxion Biosciences .....	169
Foundation Medicine.....	170
Freenome .....	171
Genomic Health .....	172
GenomOncology .....	174
GRAIL .....	175

Guardant Health .....	177
HaliuDx.....	178
Horizon Discovery .....	179
HTG Molecular Diagnostics.....	181
iCellate .....	183
Illumina.....	184
Incell Dx .....	186
Inivata.....	187
Integrated Diagnostics.....	188
Invivoscribe .....	189
Leica Biosystems .....	191
Luminex.....	192
MDx Health.....	194
Merck & Co., Inc.....	196
MIODx .....	197
Molecular MD .....	198
MRM Proteomics Inc.....	199
Myriad Genetics/Myriad RBM .....	200
Nanostring .....	202
Natera.....	204
Neogenomics .....	206
New Oncology .....	208
Oncocyte .....	209
Ortho Clinical Diagnostics .....	210
Perkin Elmer .....	211

Personal Genome Diagnostics.....	213
Pfizer.....	214
Promega.....	215
Protagen Diagnostics.....	217
Qiagen.....	218
Quanterix.....	220
Rarecells SAS.....	221
Roche Diagnostics.....	223
Siemens.....	225
Silicon Biosystems.....	226
SkylineDx.....	227
SRI International.....	228
Sysmex.....	230
Thermo Fisher.....	231
Trovagene.....	233
Vortex Biosciences.....	234
7. The Global Market for Immuno-Oncology Diagnostics.....	235
7.1 Global Market Overview by Country.....	236
7.1.1 Table – Global Market by Country.....	236
7.1.2 Chart - Global Market by Country.....	237
7.2 Global Market by Assay Type - Overview.....	238
7.2.1 Table – Global Market by Assay Type.....	238
7.2.2 Chart – Global Market by Assay Type – Base/Final Year Comparison.....	239
7.2.3 Chart – Global Market by Assay Type – Base Year.....	240
7.2.4 Chart – Global Market by Assay Type – End Year.....	241

7.2.5 Chart – Global Market by Assay Type – Share by Year .....	242
7.2.6 Chart – Global Market by Assay Type – Segments Growth.....	243
8. Global Immuno-Oncology Diagnostic Markets – By Assay Type .....	244
8.1 Checkpoint .....	245
8.1.1 Table Checkpoint – by Country .....	245
8.1.2 Chart - Checkpoint Growth.....	246
8.2 Cytokine .....	247
8.2.1 Table Cytokine – by Country .....	247
8.2.2 Chart - Cytokine Growth.....	248
8.3 Germline Genetic .....	249
8.3.1 Table Germline Genetic – by Country.....	249
8.3.2 Chart - Germline Genetic Growth .....	250
8.4 Genetic Tumor .....	251
8.4.1 Table Genetic Tumor – by Country .....	251
8.4.2 Chart - Genetic Tumor Growth .....	252
8.5 Tumor Microenvironment.....	253
8.5.1 Table Tumor Microenvironment – by Country .....	253
8.5.2 Chart – Tumor Microenvironment Growth .....	254
8.6 Other.....	255
8.6.1 Table Other – by Country.....	255
8.6.2 Chart - Other Growth .....	256
9. Appendices.....	257
9.1 FDA Cancer Drug Approvals by Year.....	258
9.2 Clinical Trials Started 2010 to 2016 .....	259
9.3 Prevalence of Cancer Treatments .....	260



## Table of Tables

Table 1 List of Cancers by Mortality .....	27
Table 2 Lab Spending 2014 to 2024 .....	33
Table 3 Overview of Innate and Adaptive Immunity .....	36
Table 4 FDA Approved Monoclonal Antibodies in Cancer treatment .....	51
Table 5 FDA Approved Companion diagnostics in Cancer treatment .....	58
Table 6 Market Players by Type .....	64
Table 7 Five Factors Driving Growth .....	71
Table 8 Three Factors Limiting Growth.....	74
Table 9 - Global Market by Region.....	236
Table 10 Global Market by Assay Type .....	238
Table 11 Checkpoint by Country .....	245
Table 12 Cytokine by Country .....	247
Table 13 Germline Genetic by Country .....	249
Table 14 Genetic Tumor by Country.....	251
Table 15 Tumor Microenvironment by Country .....	253
Table 16 Other by Country .....	255

## Table of Figures

Figure 1 Cancer Death Rates – USA, CDC .....	26
Figure 2 Clinical Lab Spending 2014 to 2024 .....	32
Figure 3 Helper T Cell Roles .....	44
Figure 4 Antibody Diagram .....	46
Figure 5 Macrophages attack a Cancer Cell .....	47
Figure 6 The Tumour Micro Environment.....	61
Figure 7 Comparing IO Diagnostic and Traditional Testing.....	79
Figure 8 Growth rates of IO Diagnostic Technologies.....	82
Figure 9 Global Market Density Chart .....	237
Figure 10 Global Market by Assay Type - Base vs. Final.....	239
Figure 11 Global Market by Assay Type Base Year .....	240
Figure 12 Global Market by Assay Type End Year.....	241
Figure 13 Assay Type Share by Year .....	242
Figure 14 Assay Type Segments Growth.....	243
Figure 15 Checkpoint Growth .....	246
Figure 16 Cytokine Growth .....	248
Figure 17 Germline Genetic Growth .....	250
Figure 18 Genetic Tumor Growth.....	252
Figure 19 Tumor Microenvironment Growth .....	254
Figure 20 Other Growth.....	256
Figure 21 FDA Cancer Drug Approvals by Year .....	258
Figure 22 Clinical Trials for Immunotherapy by Year .....	259

Figure 23 Pie Chart of Prevalence of Cancer Treatments .....260